Gilead Cancer Drug Acquisition Expands Pipeline

Snack-Sized Version:

Gilead Sciences agreed to acquire a cancer drug from Repare Therapeutics for up to $30 million. The deal includes a $25 million upfront payment, plus an additional $5 million for technology transfer. The asset, RP-3467, is a Polθ ATPase inhibitor currently in a Phase 1 trial. Therefore, researchers are evaluating it for treating several types of cancer. Consequently, this transaction marks Repare’s third and most significant portfolio deal this year. As a result, the upfront payment increases Repare’s cash balance. This also increases the estimated payout to its shareholders from a separate acquisition agreement.

Read the Full Meal:

Gilead Sciences is acquiring a cancer drug candidate from Repare Therapeutics. The deal for RP-3467 is worth up to $30 million. Specifically, Gilead will make a $25 million upfront payment. It will also pay another $5 million after technology transfer activities. The drug is a Polθ ATPase inhibitor currently in a Phase 1 trial. Consequently, the trial is evaluating its use against ovarian, breast, prostate, and pancreatic cancers. This transaction boosts Repare’s cash balance, and therefore increases the estimated payout for its shareholders under a separate acquisition agreement.

Gilead Expands Oncology Pipeline with $30M Asset Purchase

• Deal Structure: Gilead will pay $25 million upfront with an additional $5 million tied to technology transfer.
• Pipeline Asset: The acquired asset, RP-3467, is a Polθ ATPase inhibitor in a Phase 1 trial for several cancers.
• Impact on Repare: This deal increases Repare’s cash balance and the estimated payout to its shareholders.

Why this can matter for NASDAQ:GILD holders

• Oncology Strategy: Gilead is expanding its oncology pipeline by acquiring a potential best-in-class inhibitor.
• Capital Allocation: This transaction represents a focused, capital-efficient way to add a new cancer asset to its portfolio.
• Market Reaction: Gilead’s stock saw minimal movement, because the deal size is not material to its overall valuation.

For more details, see GILD SEC filings.

What to watch next

1. Milestone Payment: Monitor for the completion of technology transfer activities, which triggers the $5 million payment.
2. Clinical Trial Data: Watch for future updates or data from the POLAR Phase 1 trial for RP-3467.

Mini FAQ

What did Gilead acquire from Repare Therapeutics?
Gilead acquired RP-3467, which is a cancer drug candidate. It is a polymerase theta (Polθ) ATPase inhibitor. Consequently, it is currently being evaluated in a Phase 1 clinical trial.

How much did Gilead pay for the asset?
Gilead agreed to pay up to $30 million in total. This includes a $25 million upfront payment, plus an additional $5 million payment after completing technology transfer activities.

Why is this deal significant for Repare Therapeutics?
This is Repare’s third and most significant portfolio transaction this year. As a result, the deal increases the company’s cash balance. It also boosts the estimated cash payout its shareholders will receive.

See Also

• Gilead Sciences Inc. News Hub
• Boyd Gaming Draws New Look as Citi Initiates Coverage
• Deckers Outdoor (DECK) Upgraded to Buy by Stifel